Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival
Jiang, Jinmai , Gusev, Yuriy , Aderca, Ileana, Mettler, Teresa A., Nagorney, David M. , Brackett, Daniel J., Roberts, Lewis R. , Schmittgen, Thomas D. , Roberts, Lewis R

Mayo Clinic

Clinical Cancer Research | January 25, 2008 | Volume: 14 | Issue: 2 | Pages: 419-427

10.1158/1078-0432.ccr-07-0523 | PMID 18223217 Get It

Abstract Purpose: MicroRNA (miRNA) is a new class of small, noncoding RNA. The purpose of this study was to determine if miRNAs are differentially expressed in hepatocellular carcinoma (HCC). Experimental Design: More than 200 precursor and mature miRNAs were profiled by real-time PCR in 43 and 28 pairs of HCC and adjacent benign liver, respectively, and in normal liver specimens. Results: Several miRNAs including miR-199a, miR-21, and miR-301 were differentially expressed in the tumor compared with adjacent benign liver. A large number of mature and precursor miRNAs were up-regulated in the adjacent benign liver specimens that were both cirrhotic and hepatitis-positive compared with the uninfected, noncirrhotic specimens (P < 0.01). Interestingly, all of the miRNAs in this comparison had increased expression and none were decreased. The expression of 95 randomly selected mRNAs was not significantly altered in the cirrhotic and hepatitis-positive specimens, suggesting a preferential increase in the transcription of miRNA. Comparing the miRNA expression in the HCC tumors with patient's survival time revealed two groups of patients; those with predominantly lower miRNA expression and poor survival and those with predominantly higher miRNA expression and good survival (P < 0.05). A set of 19 miRNAs significantly correlated with disease outcome. A number of biological processes including cell division, mitosis, and G1-S transition were predicted to be targets of the 19 miRNAs in this group. Conclusion: We show that a global increase in the transcription of miRNA genes occurs in cirrhotic and hepatitis-positive livers and that miRNA expression may prognosticate disease outcome in HCC.
Noncathartic CT Colonography with Stool Tagging: Performance With and Without Electronic Stool Subtraction
Johnson, C. Daniel, MacCarty, Robert L., Carston, Michael J., Harmsen, William S. , Mandrekar, Jay , Manduca, Armando , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | January 22, 2008 | Volume: 190 | Issue: 2 | Pages: 361-366

10.2214/ajr.07.2700 | PMID 18212221 Get It

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
Hedrick, Eric, Mass, R., Sarkar, Somnath , Suzuki, Sam, Ramanathan, Ramesh K., Hurwitz, Herbert I. , Goldberg, Richard M. , Sargent, Daniel J. , Grothey, Axel , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | January 8, 2008 | Volume: 26 | Issue: 2 | Pages: 183-189

10.1200/jco.2007.13.8099 | PMID 18182660 Get It

Purpose In the phase III study AVF2107g, bevacizumab (BV) demonstrated a survival benefit when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal cancer (mCRC). In a parallel phase III study, Intergroup N9741, oxaliplatin plus fluorouracil and leucovorin (FOLFOX) also demonstrated a survival benefit compared with IFL. As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response. Patients and Methods For these retrospective, exploratory analyses, patients were defined as responders or nonresponders by whether complete or partial response was achieved with first-line therapy. Results Compared with IFL alone, BV plus IFL and FOLFOX each demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) regardless of objective tumor response. BV-treated nonresponders had a hazard ratio (HR) of 0.63 (P = .0001) for PFS and 0.76 (P = .0188) for OS compared with IFL-treated nonresponders. FOLFOX-treated nonresponders had an HR of 0.75 (P = .0029) for PFS and 0.74 (P = .0030) for OS compared with IFL-treated nonresponders. Conclusion In both AVF2107g and N9741, objective response did not predict the magnitude of PFS or OS benefit from the superior therapy; nonresponders, despite a poorer prognosis than responders, achieved extended PFS and OS from BV plus IFL or FOLFOX compared with IFL. On the basis of these data, tumor response in metastatic colorectal cancer is not a necessary factor for a therapy to provide benefit to an individual patient.
Acridine-Based Agents with Topoisomerase II Activity Inhibit Pancreatic Cancer Cell Proliferation and Induce Apoptosis
Goodell, John R. , Ougolkov, Andrei V., Hiasa, Hiroshi , Remmel, Rory P. , Billadeau, Daniel D. , Ferguson, David M. , Ugolkov, Andrey , Kaur, Harneet

Mayo Clinic

Journal of Medicinal Chemistry | December 29, 2007 | Volume: 51 | Issue: 2 | Pages: 179-182

10.1021/jm701228e | PMID 18163538 Get It

A Single-Amino-Acid Substitution in the Tvb S1 Receptor Results in Decreased Susceptibility to Infection by Avian Sarcoma and Leukosis Virus Subgroups B and D and Resistance to Infection by Subgroup E In Vitro and In Vivo
Reinišová, Markéta, Šenigl, Filip, Yin, Xueqian , Plachý, Jiřı́, Geryk, Josef, Federspiel, Mark J. , Hejnar, Jiřı́ , Elleder, Daniel , Svoboda, Jan

Mayo Clinic

Journal of Virology | December 20, 2007 | Volume: 82 | Issue: 5 | Pages: 2097-2105

10.1128/jvi.02206-07 | PMID 18094190 Get It

ABSTRACT The avian sarcoma and leukosis virus (ASLV) family of retroviruses contains five highly related envelope subgroups (A to E) thought to have evolved from a common viral ancestor in the chicken population. Three genetic loci in chickens determine the susceptibility or resistance of cells to infection by the subgroup A to E ASLVs. Some inbred lines of chickens display phenotypes that are somewhere in between either efficiently susceptible or resistant to infection by specific subgroups of ASLV. The tvb gene encodes the receptor for subgroups B, D, and E ASLVs. The wild-type Tvb S1 receptor confers susceptibility to subgroups B, D, and E ASLVs. In this study, the genetic defect that accounts for the altered susceptibility of an inbred chicken line, line M, to infection by ASLV(B), ASLV(D), and ASLV(E) was identified. The tvb gene in line M, tvb r2 , encodes a mutant Tvb S1 receptor protein with a substitution of a serine for a cysteine at position 125 (C125S). Here, we show that the C125S substitution in Tvb S1 significantly reduces the susceptibility of line M cells to infection by ASLV(B) and ASLV(D) and virtually eliminates susceptibility to ASLV(E) infection both in cultured cells and in the incidence and growth of avian sarcoma virus-induced sarcomas in chickens. The C125S substitution significantly reduces the binding affinity of the Tvb S1 receptor for the subgroup B, D, and E ASLV envelope glycoproteins. These are the first results that demonstrate a possible role of the cysteine-rich domain 3 in the function of the Tvb receptors.
Design and Development of a Surgical Skills Simulation Curriculum
McClusky, David A., Smith, C. Daniel

Mayo Clinic

World Journal of Surgery | December 7, 2007 | Volume: 32 | Issue: 2 | Pages: 171-181

10.1007/s00268-007-9331-9 | PMID 18066685 Get It

AbstractBackgroundA number of significant changes have forced surgical educators to re‐evaluate the adequacy of traditional forms of surgical skills training.MaterialsA review of the literature reveals that surgical simulation has emerged as a useful adjunct to help educators adjust to the demands of an ever‐changing surgical practice environment. As such, integration of simulation technology into a busy surgical training program has now become a priority for training programs worldwide.ResultsSuccessful integration requires a disciplined and dedicated approach to the appropriate use of all forms of available simulation in a well‐designed curriculum.ConclusionThis manuscript provides a discussion of how this can be achieved using a sequential, modular, criterion‐based framework, providing details of the rationale behind such an approach and current examples of how it can be integrated.
Glutathione S -Transferase T1 and M1: Gene Sequence Variation and Functional Genomics
Moyer, Ann M. , Salavaggione, Oreste E., Hebbring, Scott J. , Moon, Irene, Eckloff, Bruce W., Schaid, Daniel J. , Wieben, Eric D. , Weinshilboum, Richard M. , Hildebrandt, Michelle A.T. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Cancer Research | December 3, 2007 | Volume: 13 | Issue: 23 | Pages: 7207-7216

10.1158/1078-0432.ccr-07-0635 | PMID 18056202 Get It

Abstract Purpose: The glutathione S-transferases (GSTs) catalyze the glutathione conjugation of reactive electrophiles, including carcinogens and many antineoplastic drugs. GSTT1 and GSTM1 are polymorphically deleted, but the full range of genetic variation in these two genes has not yet been explored. We set out to systematically identify common polymorphisms in GSTT1 and GSTM1, followed by functional genomic studies. Experimental Design: First, multiplex PCR was used to determine GSTT1 and GSTM1 copy number in 400 DNA samples (100 each from 4 ethnic groups). Exons, splice junctions, and 5′-flanking regions (5′-FR) were then resequenced using DNA samples that contained at least one copy of GSTT1 or GSTM1. Results: Gene deletion frequencies among ethnic groups were from 33.5% to 73.5% for GSTT1 and from 50.5% to 78.0% for GSTM1. GSTT1 deletion data correlated with the results of mRNA microarray expression studies. The 18 single nucleotide polymorphisms (SNP) observed in GSTT1 included three nonsynonymous coding SNPs (cSNPs) and one single-nucleotide deletion, whereas the 51 GSTM1 SNPs included two nonsynonymous cSNPs. Two of the GSTT1 nonsynonymous cSNPs resulted in decreases in levels of immunoreactive protein to 56% and 12% of wild type (WT), whereas those in GSTM1 resulted in modest increases in protein levels. Reporter gene assays showed that one GSTT1 5′-FR haplotype, with a frequency of 32% in African-American subjects, resulted in an increase in transcription in JEG-3 cells to 351% of that for the WT sequence, and one GSTM1 5′-FR haplotype resulted in an increase in transcription in JEG-3 cells to 129% of WT. Conclusions: These observations suggest that functionally significant pharmacogenomic variation beyond GSTT1 and GSTM1 gene deletion may contribute to carcinogenesis or individual variation in antineoplastic drug therapy response.
Parents' Worries About Children Compared to Actual Risks
Stickler, Gunnar B., Salter, Margery, Broughton, Daniel D., Alario, Anthony J.

Mayo Clinic

Clinical Pediatrics | November 26, 2007 | Volume: 30 | Issue: 9 | Pages: 522-528

10.1177/000992289103000901 | PMID 1804584 Get It

To investigate the concerns of parents, questionnaires were given to the "first 100" parents waiting for their child's pediatric appointment in four different medical settings. They were asked to rate whether they worry "frequently," "occasionally," or "not at all" about 17 physical health issues, 16 psychosocial problems, 7 possible injuries, 4 instances of victimization, and 4 questions about parents' ability to provide discipline, affection, values and financial support. The response rate was 94% ; 89% were completed adequately for analysis. Parental concerns were compared to data from the National Center for Health Statistics about the statistical likelihood of the risks occurring. Ear infections (65%) were the most common health concern, followed by reaction to immunization (57%), common colds (51%), and cancer (50%). The greatest psychosocial concern was about children watching too much television (53%), followed by concerns about the quality of day care (50%). Three-quarters of parents worry about car accidents and 72% worry about abduction of their children. Parents worry significantly about their own contribution to their child's welfare: appropriate discipline (73%), affection (56%), values and being a role model (55%), and financial support (66%). Parents who had not completed high school worried more than parents who had more than a high school education (P < 0.03).
Weight Loss and Body Temperature Changes in Breast-fed and Bottle-fed Neonates
Podratz, Rosalyn O., Broughton, Daniel D., Bergstralh, Erik J., Melton, L. Joseph , Gustafson, David H.

Mayo Clinic

Clinical Pediatrics | November 26, 2007 | Volume: 25 | Issue: 2 | Pages: 73-77

10.1177/000992288602500202 | PMID 3943261 Get It

Among 1138 newborns in a Level II nursery, breast-fed and formula-fed infants were comparable in terms of sex, mode of delivery, gestational age, birth weight, and birth temperature. Breast-fed neonates subsequently lost more weight and a greater percentage of their birth weight (mean, 7.4% vs. 4.9%) than did formula-fed infants. Loss of more than 10 percent of birth weight was associated with short gestation and low birth weight and with breast feeding. Birth weight loss of ≥3 percent was associated with a risk of fever (≥37.5°C) among breast-fed and formula-fed infants, but there was no gradient of increasing risk of fever with increasing percentage weight loss beyond 3 percent. After weight loss and other significant variables were adjusted for in a multivariate analysis, breast feeding was not independently predictive of fever. Although breast feeding may be associated with weight loss, it is not prudent to assume that this is the cause of fever in a breast-fed neonate.
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Burzykowski, Tomasz , Carroll, Kevin , Michiels, Stefan , Sargent, Daniel J. , Miller, Langdon L., Elfring, Gary, Pignon, Jean‐Pierre , Piedbois, Pascal, Buyse, Marc , Sargent, Daniel J , Burzykowski, Tomasz

Mayo Clinic

Journal of Clinical Oncology | November 16, 2007 | Volume: 25 | Issue: 33 | Pages: 5218-5224

10.1200/jco.2007.11.8836 | PMID 18024867 Get It

Purpose The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer is overall survival (OS), but this end point requires prolonged follow-up and is potentially confounded by the effects of second-line therapies. We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in advanced colorectal cancer. Patients and Methods Individual patient data were available from 10 historical trials comparing fluouracil (FU) + leucovorin with either FU alone (1,744 patients) or with raltitrexed (1,345 patients) and from three validation trials comparing FU + leucovorin with or without irinotecan or oxaliplatin (1,263 patients). Correlation coefficients were estimated in historical trials between the end points of PFS and OS, and between the treatment effects on these end points. Treatment effects on OS were predicted in validation trials, and compared with the observed effects. Results In historical trials, 1,760 patients (57%) had progressed or died at 6 months, and 1,622 (52%) had died at 12 months. The rank correlation coefficient between PFS and OS was equal to 0.82 (95% CI, 0.82 to 0.83). The correlation coefficient between treatment effects on PFS and on OS ranged from 0.99 (95% CI, 0.94 to 1.04) when all trials were considered to 0.74 (95% CI, 0.44 to 1.04) after exclusion of one highly influential trial. In the validation trials, the observed OS hazard ratios were within the 95% prediction intervals. A hazard ratio of 0.77 or lower in terms of PFS would predict a benefit in terms of OS. Conclusion PFS is an acceptable surrogate for OS in advanced colorectal cancer.